CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure
Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Mar 4, 2014
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with chronic heart failure scheduled for LVAD
- • Indication for CVVH/Aquapheresis
- Exclusion Criteria:
- • Renal Disease (GFR \<20 ml / min)
About Heinrich Heine University, Duesseldorf
Heinrich-Heine University Düsseldorf is a leading academic institution dedicated to advancing medical research and education. Renowned for its innovative approach to healthcare and interdisciplinary collaboration, the university plays a pivotal role in clinical trials aimed at improving patient outcomes and translating scientific discoveries into clinical practice. With a robust infrastructure and a commitment to ethical standards, Heinrich-Heine University fosters an environment that supports cutting-edge research initiatives, contributing significantly to the advancement of medical knowledge and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Duesseldorf, , Germany
Patients applied
Trial Officials
Ralf Westenfeld, MD
Principal Investigator
Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf
Malte Kelm, MD
Study Chair
Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials